How we treat mature B-cell neoplasms (indolent B-cell lymphomas) Review
| Authors: | Lumish, M.; Falchi, L.; Imber, B. S.; Scordo, M.; von Keudell, G.; Joffe, E. |
| Review Title: | How we treat mature B-cell neoplasms (indolent B-cell lymphomas) |
| Abstract: | Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can be deferred for years. However, some patients will have an accelerated course and may experience transformation into aggressive lymphomas. In this review, we focus on management concepts shared across iNHLs, as well as histology-specific strategies. We address open questions in the field, including the influence of genomics and molecular pathway alterations on treatment decisions. In addition, we review the management of uncommon clinical entities including nodular lymphocyte-predominant Hodgkin lymphoma, hairy cell leukemia, splenic lymphoma and primary lymphoma of extranodal sites. Finally, we include a perspective on novel targeted therapies, antibodies, antibody–drug conjugates, bispecific T cell engagers and chimeric antigen receptor T cell therapy. © 2021, The Author(s). |
| Keywords: | treatment response; histopathology; review; splenectomy; cancer localization; cancer recurrence; advanced cancer; cancer radiotherapy; primary central nervous system lymphoma; ibritumomab tiuxetan; rituximab; cancer staging; cancer diagnosis; treatment indication; protein bcl 2; lung cancer; diagnostic imaging; tumor marker; cancer therapy; risk assessment; b cell lymphoma; active surveillance; hematopoietic cell; hematopoietic stem cell; follicular lymphoma; marginal zone lymphoma; nodular lymphocyte predominant hodgkin lymphoma; refractory period; hairy cell leukemia; skin lymphoma; phosphatidylinositol 3 kinase inhibitor; molecularly targeted therapy; transcription factor ezh2; systemic disease; intraocular lymphoma; gastrointestinal lymphoma; indolent lymphoma; cancer prognosis; idelalisib; ibrutinib; human; copanlisib; duvelisib; polatuzumab vedotin; venetoclax; oncogenomics; antibody drug conjugate; chimeric antigen receptor t-cell immunotherapy; acalabrutinib; bruton tyrosine kinase inhibitor; zanubrutinib; parsaclisib; umbralisib; mature b cell neoplasm; magrolimab; mosunetuzumab; zandelisib; splenic marginal zone lymphoma |
| Journal Title: | Journal of Hematology & Oncology |
| Volume: | 14 |
| ISSN: | 1756-8722 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-01-06 |
| Start Page: | 5 |
| Language: | English |
| DOI: | 10.1186/s13045-020-01018-6 |
| PROVIDER: | scopus |
| PMCID: | PMC7789477 |
| PUBMED: | 33407745 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 February 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work